The researchers believe that such aging-independent drug effects also underlie rapamycin's effect on lifespan. "We assume that the lifespan of mice is extended because rapamycin inhibits tumor formation. This is a well-known rapamycin effect, which we were able to confirm. Cancer is the leading cause of death in the relevant mouse strains" says the specialist in molecular medicine. "Rapamycin, therefore, seems to have isolated effects on specific life-limiting pathology, but lacks broad effects on aging in mice."
A comprehensive assessment of aging
The research team assessed more than 150 traits, which typically change during the course of aging. These analyses included an assessment of vision, reflexes, cardiovascular function, learning and behavior, immune functions and the integrity of the arterial wall, to just name a few. "Aging is a complex process, which cannot be captured by assessing a single parameter. This is why we analysed a large number of structural and functional signs of aging," explains Ehninger. "The present study is one of the most comprehensive assessments of a putative anti-aging intervention."
The analysis comprised three different age cohorts, in which rapamycin treatment was either initiated in young adulthood, in midlife or late in life. "At the time, the US study showed that rapamycin extends lifespan irrespective of whether the treatment is given to young or aged animals," says the Bonn-based researcher. "We, therefore, chose a study design, in the context of which we also investiga
|Contact: Dr. Dirk Förger|
Helmholtz Association of German Research Centres